A newly approved drug marks a significant advancement in the treatment of narcolepsy by targeting the disorder’s underlying cause rather than merely alleviating its symptoms. Orezyful, developed by Takeda Pharmaceutical Co., is the first medication designed to replace orexin, a crucial brain peptide absent in people with type 1 narcolepsy. The Food and Drug Administration (FDA) approved the drug last month, offering hope to the estimated 120,000 Americans affected by this condition.
Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness and episodes of cataplexy, sudden muscle weakness often triggered by strong emotions. For many patients, the disorder impairs memory and attention and profoundly disrupts daily life. Julie Flygare, diagnosed with narcolepsy in 2007, described the condition as a persistent “heaviness on the skull.” While existing treatments provide limited relief, many patients, including Flygare, have long awaited a therapy that addresses the disease’s root cause.
Orexin, produced by brain cells in the hypothalamus, regulates wakefulness by binding to specific receptors. People with type 1 narcolepsy lack this chemical, making it difficult for them to stay awake or prevent muscle weakness during emotional episodes. Takeda’s Orezyful is designed as an “agonist,” activating orexin receptors to compensate for the deficiency.
The drug’s approval followed two late-stage clinical trials involving nearly 300 participants aged 16 to 70. Patients receiving Orezyful demonstrated the ability to remain awake for more than 20 minutes during the maintenance of wakefulness test, roughly double the duration achieved with current medications. The test, conducted in dimly lit rooms where patients must stay awake without external stimulation, typically poses a major challenge for those with narcolepsy. These findings were published recently in The New England Journal of Medicine.
Experts unaffiliated with the trials described Orezyful as potentially transformative. Dr. Thomas Scammell of Beth Israel Deaconess Medical Center noted that some patients reported renewed abilities to engage in activities such as dancing, sports, and socializing. Flygare, who participated in one of the trials, recounted the stark contrast in her functioning before and after starting the drug, highlighting its impact on her quality of life.
Despite enthusiasm among clinicians, some questions remain regarding Orezyful’s long-term effects and safety profile, as well as how activating orexin receptors might influence the risk of other neurological conditions. The drug will not become commercially available until the U.S. Drug Enforcement Administration classifies it, a process expected to conclude by November.
The journey to this medical milestone began more than twenty years ago, when researchers identified the orexin deficit as the cause of narcolepsy. Developing a drug that effectively mimics orexin’s natural activity proved challenging. Early candidates faced hurdles such as administration difficulties and toxicity. Takeda’s persistent research and screening efforts ultimately overcame these obstacles.
Other pharmaceutical companies are pursuing similar therapies. Alkermes and Centessa Pharmaceuticals, now owned by Eli Lilly, have drugs in advanced stages of development targeting orexin pathways. Industry observers anticipate that such treatments could eventually extend beyond sleep disorders to tackle conditions like attention deficit hyperactivity disorder, Alzheimer’s disease, Parkinson’s disease, and post-traumatic stress disorder, given orexin’s broader role in neurological health.
For patients like Flygare, the approval of Orezyful represents a pivotal moment in narcolepsy care, potentially shifting the trajectory of a disease that has long been misunderstood and underserved.